comparemela.com

Latest Breaking News On - Prevent invasive pneumococcal disease - Page 1 : comparemela.com

FDA Drug Approval Decisions Expected in June 2024

The PDUFA date refers to the deadline set by the US Food and Drug Administration for reviewing drug applications.

Drug administrationInternational prognostic scoring systemPrescription drug user fee actNew drug applicationBiologics license applicationPriority reviewPrimary biliaryAdvanced small cell lungLower risk myelodysplasticPrevent invasive pneumococcal diseaseMaintenance treatment

Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults

12.07.2022 - - Company Expects to Announce Topline Results from the Phase 1 and Phase 2 Portions of the Proof-of-Concept Study in October or November 2022 - - Vaxcyte Also Dosed First Participants in Separate VAX-24 Phase 2 Clinical Study in Adults 65 Years and . Seite 1

Vaxcyte incValent pneumococcal conjugate vaccine designedDeliver broad spectrum protectionPrevent invasive pneumococcal disease

vimarsana © 2020. All Rights Reserved.